Tetanus and rabies vaccine samples fail quality test at Central Drugs Laboratory, Kasauli

Shimla, 7 September: In a recent quality control check, three samples of tetanus toxoid vaccine and one sample of rabies antiserum failed to meet the required standards at the Central Drugs Laboratory (CDL) in Kasauli. This takes the total number of failed samples to five, as confirmed on the CDL website. The failure of these crucial vaccines raises concerns about their safety and efficacy, leading to an ongoing investigation into the reasons behind the substandard results.

The concerned agency responsible for vaccine production has already been informed, and the CDL has forwarded its findings to the Ministry of Health. A team of experts is currently investigating the cause of the sample failures, with a detailed report expected soon. The Ministry of Health will decide on further action based on the investigation report, which may include recalling the affected vaccine batches or stopping their distribution.

CDL Kasauli plays a vital role in protecting public health by testing all vaccines manufactured, imported or exported to India. The laboratory ensures that only vaccines that pass strict quality control measures enter the market. In cases where even a single sample fails the test, the entire batch is withheld from distribution until the issue is resolved.

During the COVID-19 pandemic, CDL Kasauli was responsible for testing various vaccines used across the country to ensure their safety before mass vaccinations are carried out. Currently, the laboratory continues to conduct tests on several vaccines to maintain quality control and ensure public safety.

Implications of failed samples
The failure of the tetanus toxoid vaccine and rabies antiserum is worrisome, as these are crucial to prevent serious infections. Tetanus toxoid is commonly used to prevent tetanus, a potentially fatal bacterial infection, while rabies antiserum is crucial in treating rabies, which can be fatal if not treated promptly.

Now that the failed samples are being investigated, the health ministry will decide on further action, which could include halting distribution of the affected batches or conducting further quality checks. Public health experts stress the importance of stringent quality control to maintain confidence in vaccines and ensure they are both safe and effective.